View ValuationProteome Sciences 将来の成長Future 基準チェック /06現在、 Proteome Sciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長20.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Feb 03Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021Proteome Sciences plc provides earnings guidance for the financial year ended 31 December 2021. For the period, the company expects to report a 7% increase in Group revenues to £5.1 million (2020: £4.75 million) for the full year, with services expected to increase 32% to £1.9 million (2020: £1.44 million) and sales and royalties attributable to TMT® and TMTpro™ reagents to be £3.2 million (2020: £3.27 million). The Company anticipates an estimated trading profit of between £0.6 million and £0.8 million (2020: £0.50 million) (excluding interest, currency and share based payments effects) which shows a positive development of the operational business.すべての更新を表示Recent updatesBoard Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 5 highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdomお知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation Sお知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct Listingお知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdomお知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025New Risk • Nov 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.77m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (€8.77m market cap, or US$9.53m).New Risk • Sep 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.80m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (€8.80m market cap, or US$9.83m).New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 49% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€9.97m market cap, or US$11.0m).お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.Reported Earnings • Apr 10Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)Full year 2023 results: UK£0.008 loss per share (down from UK£0.004 profit in FY 2022). Revenue: UK£5.03m (down 35% from FY 2022). Net loss: UK£2.44m (down 284% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United KingdomNew Risk • Mar 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.4m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€14.3m market cap, or US$15.6m).お知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.Buying Opportunity • Aug 28Now 43% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.086, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 64%.Reported Earnings • Aug 26First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.002 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£3.21m (down 1.0% from 1H 2022). Net loss: UK£578.0k (down UK£641.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 64% per year whereas the company’s share price has increased by 68% per year.Buying Opportunity • Jul 07Now 33% undervaluedOver the last 90 days, the stock is up 154%. The fair value is estimated to be €0.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 76%.Reported Earnings • Apr 08Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0.004 (up from UK£0 in FY 2021). Revenue: UK£7.78m (up 52% from FY 2021). Net income: UK£1.33m (up UK£1.25m from FY 2021). Profit margin: 17% (up from 1.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 18Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial OfficerThe Board of Proteome Sciences plc announced that Abdel ghani Omarihas been appointed as the Company's new Chief Financial Officer. He will take up the position on September 1st, 2022 and will become a director of the Company. Abdel joins Proteome Sciences from Paion AG, a listed speciality pharmaceutical company, where he has been CFO and since 2014 a member of the management board. During his time at Paion he has negotiated numerous license agreements with pharma companies and has raised more than EUR 150 million in financing from investors in the U.S. and in Europe. In addition to the finance role, Abdel was also responsible for HR, IT, Legal, IP & Compliance and more recently investor relations. Abdel has more than 20 years' experience in finance, starting his career at KPMG Audit after a business degree from the University of Aachen. At KPMG he worked in audit and financial consultancy roles prior to joining Paion. Proteome Sciences' Chief Executive Officer, Dr. Mariola Soehngen, commented "The Board and the Company welcome Abdel as Proteome Sciences' CFO at this important point in the company's growth. Abdel brings a wealth of relevant experience to the team as pursue the Company´s strategy of organic growth, to grow the business through adding new high value services to portfolio and enter into further internationalization of the business.Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£425.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 04Proteome Sciences plc Completes Milestone Towards Launch of single Cell Proteomics ServicesProteome Sciences plc announced that the Company has completed the next milestone towards the launch of Single Cell Proteomics services, which will be known as SysQuant® SCP, with the installation of a cellenONE® (Cellenion, France) platform that allows the semi-automated preparation of up to 2,700 cells per week. The Company anticipates that most commercial projects will require analysis of 500 - 1,000 cells using TMTpro™ multiplexing, and it will be able to perform 1-2 such studies per week. Working with such small samples is challenging and will be beyond the means of many academic and industrial research groups. The Company believes its employees' experience as inventors and manufacturers of TMT® and TMTpro reagents gives the Company unique insights into their use in this complex setting.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)Full year 2021 results: EPS: UK£0 (down from UK£0.001 in FY 2020). Revenue: UK£5.13m (up 7.9% from FY 2020). Net income: UK£72.0k (down 76% from FY 2020). Profit margin: 1.4% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Mar 31Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 38%. The fair value is estimated to be €0.041, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company has become profitable.お知らせ • Mar 31Proteome Sciences plc, Annual General Meeting, May 16, 2022Proteome Sciences plc, Annual General Meeting, May 16, 2022, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London, EC3A 6AB London United Kingdomお知らせ • Mar 29Proteome Sciences plc to Report Fiscal Year 2021 Results on Mar 31, 2022Proteome Sciences plc announced that they will report fiscal year 2021 results on Mar 31, 2022Buying Opportunity • Mar 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.044, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.Buying Opportunity • Feb 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.051, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.お知らせ • Feb 03Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021Proteome Sciences plc provides earnings guidance for the financial year ended 31 December 2021. For the period, the company expects to report a 7% increase in Group revenues to £5.1 million (2020: £4.75 million) for the full year, with services expected to increase 32% to £1.9 million (2020: £1.44 million) and sales and royalties attributable to TMT® and TMTpro™ reagents to be £3.2 million (2020: £3.27 million). The Company anticipates an estimated trading profit of between £0.6 million and £0.8 million (2020: £0.50 million) (excluding interest, currency and share based payments effects) which shows a positive development of the operational business.Reported Earnings • Aug 03First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.97m (up 3.7% from 1H 2020). Net loss: UK£425.0k (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Apr 21Independent Non Executive Director recently bought €52k worth of stockOn the 16th of April, Roger McDowell bought around 900k shares on-market at roughly €0.058 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €89k more in shares than they have sold in the last 12 months.Reported Earnings • Apr 03Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£4.75m (up 2.1% from FY 2019). Net income: UK£295.0k (up 98% from FY 2019). Profit margin: 6.2% (up from 3.2% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Proteome Sciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:PI2 - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20254-300N/A9/30/20254-3-1-1N/A6/30/20255-3-1-1N/A3/31/20255-3-1-1N/A12/31/20245-3-1-1N/A9/30/20244-4-2-1N/A6/30/20244-4-2-2N/A3/31/20245-3-1-1N/A12/31/20235-2-10N/A9/30/20236-111N/A6/30/20238122N/A3/31/20238122N/A12/31/20228122N/A9/30/20227122N/A6/30/20226122N/A3/31/20226011N/A12/31/20215011N/A9/30/20215011N/A6/30/20215011N/A3/31/20215011N/A12/31/20205022N/A9/30/20205011N/A6/30/20205011N/A3/31/20205000N/A12/31/20195000N/A9/30/201940N/A0N/A6/30/201930N/A0N/A3/31/20193-1N/A0N/A12/31/20183-1N/A-1N/A9/30/20183-2N/A0N/A6/30/20183-2N/A0N/A3/31/20183-2N/A-1N/A12/31/20173-2N/A-2N/A9/30/20173-2N/A-2N/A6/30/20173-2N/A-3N/A3/31/20173-2N/A-2N/A12/31/20163-2N/A-2N/A9/30/20162-3N/A-2N/A6/30/20162-3N/A-2N/A3/31/20162-3N/A-2N/A12/31/20152-3N/A-2N/A9/30/20152-3N/A-3N/A6/30/20152-3N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PI2の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PI2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PI2の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PI2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PI2の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PI2の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 14:26終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Proteome Sciences plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMichael Thomas CooperEdison Investment Research
お知らせ • Feb 03Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021Proteome Sciences plc provides earnings guidance for the financial year ended 31 December 2021. For the period, the company expects to report a 7% increase in Group revenues to £5.1 million (2020: £4.75 million) for the full year, with services expected to increase 32% to £1.9 million (2020: £1.44 million) and sales and royalties attributable to TMT® and TMTpro™ reagents to be £3.2 million (2020: £3.27 million). The Company anticipates an estimated trading profit of between £0.6 million and £0.8 million (2020: £0.50 million) (excluding interest, currency and share based payments effects) which shows a positive development of the operational business.
Board Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 5 highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.
お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdom
お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation S
お知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom
お知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025
New Risk • Nov 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.77m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (€8.77m market cap, or US$9.53m).
New Risk • Sep 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.80m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (€8.80m market cap, or US$9.83m).
New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 49% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€9.97m market cap, or US$11.0m).
お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.
Reported Earnings • Apr 10Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)Full year 2023 results: UK£0.008 loss per share (down from UK£0.004 profit in FY 2022). Revenue: UK£5.03m (down 35% from FY 2022). Net loss: UK£2.44m (down 284% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United Kingdom
New Risk • Mar 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.4m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€14.3m market cap, or US$15.6m).
お知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.
Buying Opportunity • Aug 28Now 43% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be €0.086, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 64%.
Reported Earnings • Aug 26First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.002 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£3.21m (down 1.0% from 1H 2022). Net loss: UK£578.0k (down UK£641.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 64% per year whereas the company’s share price has increased by 68% per year.
Buying Opportunity • Jul 07Now 33% undervaluedOver the last 90 days, the stock is up 154%. The fair value is estimated to be €0.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 76%.
Reported Earnings • Apr 08Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0.004 (up from UK£0 in FY 2021). Revenue: UK£7.78m (up 52% from FY 2021). Net income: UK£1.33m (up UK£1.25m from FY 2021). Profit margin: 17% (up from 1.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 18Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial OfficerThe Board of Proteome Sciences plc announced that Abdel ghani Omarihas been appointed as the Company's new Chief Financial Officer. He will take up the position on September 1st, 2022 and will become a director of the Company. Abdel joins Proteome Sciences from Paion AG, a listed speciality pharmaceutical company, where he has been CFO and since 2014 a member of the management board. During his time at Paion he has negotiated numerous license agreements with pharma companies and has raised more than EUR 150 million in financing from investors in the U.S. and in Europe. In addition to the finance role, Abdel was also responsible for HR, IT, Legal, IP & Compliance and more recently investor relations. Abdel has more than 20 years' experience in finance, starting his career at KPMG Audit after a business degree from the University of Aachen. At KPMG he worked in audit and financial consultancy roles prior to joining Paion. Proteome Sciences' Chief Executive Officer, Dr. Mariola Soehngen, commented "The Board and the Company welcome Abdel as Proteome Sciences' CFO at this important point in the company's growth. Abdel brings a wealth of relevant experience to the team as pursue the Company´s strategy of organic growth, to grow the business through adding new high value services to portfolio and enter into further internationalization of the business.
Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£425.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 04Proteome Sciences plc Completes Milestone Towards Launch of single Cell Proteomics ServicesProteome Sciences plc announced that the Company has completed the next milestone towards the launch of Single Cell Proteomics services, which will be known as SysQuant® SCP, with the installation of a cellenONE® (Cellenion, France) platform that allows the semi-automated preparation of up to 2,700 cells per week. The Company anticipates that most commercial projects will require analysis of 500 - 1,000 cells using TMTpro™ multiplexing, and it will be able to perform 1-2 such studies per week. Working with such small samples is challenging and will be beyond the means of many academic and industrial research groups. The Company believes its employees' experience as inventors and manufacturers of TMT® and TMTpro reagents gives the Company unique insights into their use in this complex setting.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)Full year 2021 results: EPS: UK£0 (down from UK£0.001 in FY 2020). Revenue: UK£5.13m (up 7.9% from FY 2020). Net income: UK£72.0k (down 76% from FY 2020). Profit margin: 1.4% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Mar 31Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 38%. The fair value is estimated to be €0.041, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company has become profitable.
お知らせ • Mar 31Proteome Sciences plc, Annual General Meeting, May 16, 2022Proteome Sciences plc, Annual General Meeting, May 16, 2022, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London, EC3A 6AB London United Kingdom
お知らせ • Mar 29Proteome Sciences plc to Report Fiscal Year 2021 Results on Mar 31, 2022Proteome Sciences plc announced that they will report fiscal year 2021 results on Mar 31, 2022
Buying Opportunity • Mar 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.044, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
Buying Opportunity • Feb 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.051, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
お知らせ • Feb 03Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021Proteome Sciences plc provides earnings guidance for the financial year ended 31 December 2021. For the period, the company expects to report a 7% increase in Group revenues to £5.1 million (2020: £4.75 million) for the full year, with services expected to increase 32% to £1.9 million (2020: £1.44 million) and sales and royalties attributable to TMT® and TMTpro™ reagents to be £3.2 million (2020: £3.27 million). The Company anticipates an estimated trading profit of between £0.6 million and £0.8 million (2020: £0.50 million) (excluding interest, currency and share based payments effects) which shows a positive development of the operational business.
Reported Earnings • Aug 03First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.97m (up 3.7% from 1H 2020). Net loss: UK£425.0k (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Apr 21Independent Non Executive Director recently bought €52k worth of stockOn the 16th of April, Roger McDowell bought around 900k shares on-market at roughly €0.058 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €89k more in shares than they have sold in the last 12 months.
Reported Earnings • Apr 03Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£4.75m (up 2.1% from FY 2019). Net income: UK£295.0k (up 98% from FY 2019). Profit margin: 6.2% (up from 3.2% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.